All News

The approval is supported by data from the phase 3 TROPION-Breast02 trial.

GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.

This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.

Pharmacists can use immunization registry data, collaborative practice agreements, and evidence-based vaccine advocacy to close adult hepatitis B care gaps.

GLP-1 receptor agonists may reduce asthma flare-ups in nondiabetic adults with obesity, hinting at anti-inflammatory benefits.

Identifying inappropriate OTC medications and recommending safer pharmacotherapy treatments are important roles for pharmacists.

Pharmacy Times speaks with Helen Latimer, MPH, to discuss the advancement of HRR genetic testing equity in metastatic prostate cancer.

Hemophilia management is shifting from traditional intravenous therapies toward subcutaneous agents.

GLP-1 receptor agonists could influence endometrial cancer prevention, obesity management, fertility preservation, and molecularly guided treatment strategies in gynecologic oncology.

Eli Lilly's investigational triple hormone receptor agonist achieved average weight loss of up to 70.3 lb over 80 weeks.

A retrospective cohort study determined that individuals who consumed less than 1.0 g/kg/day of protein had significantly better kidney-related outcomes over 15 years of follow-up.

Expert highlights why hepatitis B vaccination remains an urgent priority for adult patients and why the 2-dose Heplisav-B regimen's faster seroprotection offers meaningful public health advantages over the traditional 3-dose series.

Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.

Pharmacy Times speaks with Jeff Goad, PhD, MPH, about the biggest misconceptions surrounding measles and the MMR vaccine, as well as the serious symptoms pharmacists believe patients should never ignore.

Use 5 checks to keep your emergency fund right-sized, earning more, and separated—so setbacks don’t wreck your finances.

Prior authorizations, injection site shortages, and care transition failures are undermining LAI antipsychotic adherence in patients with schizophrenia, one pharmacist explains.

Neurology trial tests low-dose lithium for MCI and Alzheimer risk; results miss primary end points but hint at slower verbal memory decline.

Jessica Geiger, PharmD, weighs ketamine in palliative care—pain relief, opioid-sparing evidence, stigma, and safety considerations for hospice patients.

Perioperative durvalumab and tremelimumab plus neoadjuvant enfortumab vedotin improves survival in muscle-invasive bladder cancer.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

As agentic AI enters clinical workflows, the real risk isn't processing power—it's whether AI systems can consistently access authoritative, real-time medication intelligence.

Researchers at Northwestern University have uncovered a surprising new role for montelukast that could reshape how oncologists approach immunotherapy resistance.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, explores the most significant advancements in continuous glucose monitoring (CGM) and automated insulin delivery in 2026.

Pharmacy Times interviews Sarah Spark, MHA, MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of real-world oncology data to better support clinical decision-making, research, and patient outcomes.

FACT-accredited centers vs nonaccredited centers may influence CAR T-cell therapy outcomes.

The drug is currently under priority review by the FDA with a final decision expected by June 16, 2026.